Bicara Therapeutics Inc. (BCAX)
- Previous Close
14.47 - Open
14.10 - Bid 14.36 x 100
- Ask 14.59 x 100
- Day's Range
13.41 - 15.30 - 52 Week Range
8.91 - 28.09 - Volume
594,520 - Avg. Volume
562,483 - Market Cap (intraday)
789.139M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.69 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.60
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
www.bicara.comRecent News: BCAX
View MorePerformance Overview: BCAX
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCAX
View MoreValuation Measures
Market Cap
789.14M
Enterprise Value
327.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
-27.26%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-92.33M
Diluted EPS (ttm)
-1.69
Balance Sheet and Cash Flow
Total Cash (mrq)
462.06M
Total Debt/Equity (mrq)
0.13%
Levered Free Cash Flow (ttm)
--